Individuals Coming Off Weight-Loss Injections Regain Weight Far More Rapidly Than Dieters

Fresh analysis suggests that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise regimens.

Published data in a leading health publication points out that while overweight individuals often shed a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit.

"Users using such drugs must be cognizant of the potential of fast weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.

Such speed of regain suggests a return to pre-treatment weight within about a year and a half.

Comparing Treatments

The study, which looked at 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.

Researchers emphasize that people who lose weight through dieting generally see a less rapid weight regain—approximately 0.1 kg a month—once they finish.

The Reason for the Quick Rebound

Experts suggest the mode of action of the drugs is key to understanding the accelerated weight return.

These medications copy a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Artificially providing the hormone concentrations several times higher than normal may cause the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making binge eating much more probable."

A Lifelong Condition?

Health authorities suggest the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.

Many experts say that, considering the significant potential of weight regain, the treatment should be considered life-long.

This opinion is echoed by pharmaceutical companies, who state that the findings "underscore the long-term character of obesity," akin to managing conditions like hypertension.

User Experiences

People who have discontinued the jabs describe a powerful resurgence of appetite.

"I experienced a trigger activating and you're instantly starving," described an individual.

The struggle is exacerbated if individuals have not developed lasting dietary or behavioural changes during treatment.

Widespread Adoption

Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.

• Use is greater among females compared to males.
• The middle-aged age group shows the greatest level of interest.
• Many obtain the medications through private prescriptions rather than the NHS.

Finally, experts caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent solution and lasting health benefits likely depends on ongoing lifestyle support.